CoronaryAtlas logo
CoronaryAtlas
arginine
Pathway / Endothelial activation & erosion

arginine

metabolite

Arginine dysregulation impairs endothelial NO synthesis, reducing vasodilation and promoting endothelial dysfunction while delaying myocardial recovery from ischemic injury.

Pathway placement
Cascade stepEndothelial activation & erosion
Confidencemedium
RationaleNOS substrate; arginine dysregulation impairs endothelial NO production and contributes to myocardial ischemic injury recovery.
Also acts inMyocardial injury
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
67
A — assay feasibility
42
E — evidence strength
73
T1DI (composite)
7
Specificity differential (R−C)-51.7
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 2
7high-demand / peri-operative stressn/a
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 20 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(5)